2024-11-22
Immune checkpoint inhibitor therapy: a major breakthrough in treating triple-negative breast cancer
Oncology
ICIs: A revolution in TNBC treatment?
To explore this hypothesis, 11 randomized clinical trials involving a total of 4,314 patients with unresectable, locally advanced, or metastatic TNBC were selected. The efficacy of the treatment was assessed by analyzing the following outcomes: overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and treatment-related adverse events (TRAEs). Subgroup analyses were also conducted for PD-L1-positive patients to examine differences in response.The findings demonstrate that PD-L1 inhibitors significantly improve OS in both the intention-to-treat and PD-L1-positive populations. Additionally, PFS also increased in these groups.
While immunotherapies were associated with an increase in immune-mediated adverse events (such as hypothyroidism, skin rashes, and pneumonitis), the incidence of severe events was not higher than with chemotherapy alone.
Finally, combining ICIs with chemotherapy showed superior clinical benefits compared to monotherapy, further reinforcing their relevance in managing TNBC.
A new hope in the fight against tnbc
This study confirms the potential of PD-1/PD-L1 inhibitors to transform the treatment landscape for advanced TNBC, particularly in PD-L1-positive patients. While these findings suggest that immunotherapy could become a cornerstone strategy for managing TNBC, challenges remain. These include optimizing its use, managing adverse effects, and identifying predictive biomarkers.
Last press reviews
Eat without fear: anti-ige antibody omalizumab, a new weapon against food allergies

#Omalizumab #FoodAllergies #IgE #Anaphylaxis #Immunotherapy ...
Vitamin D and tuberculosis: an overestimated protection?

By Ana Espino | Published on July 18, 2025 | 2 min read
Outdoor temperature and severe hyponatremia: a growing threat in the age of climate change

By Lila Rouland | Published on July 17, 2025 | 3 min read ...